Generic Medicine Info
Hypersensitivity to cefotaxime or other cephalosporins. History of acute or severe hypersensitivity reaction to penicillin or other β-lactam antibiotics. Concomitant use with bacteriostatic antibiotics (e.g. tetracyclines, erythromycin, chloramphenicol).
Special Precautions
Patient with asthma, allergic diathesis, history of gastrointestinal disease (particularly colitis). Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests prior to therapy; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor CBC with differential (particularly with prolonged use of >10 days) and renal function. Assess for signs or symptoms of anaphylaxis during initial dose.
Adverse Reactions
Significant: Fungal or bacterial superinfection; serious bullous skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis); neutropenia, leucopenia, eosinophilia, thrombocytopenia, granulocytopenia, haemolytic anaemia (prolonged use); encephalopathy with focal motor status and generalised convulsion (in patients with renal insufficiency). Rarely, agranulocytosis (prolonged use). Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain. General disorders and administration site conditions: Inj site pain (IM); fever, inflammatory reactions at the inj site (e.g. phlebitis, thrombophlebitis). Hepatobiliary disorders: Hepatitis (occasionally with jaundice). Immune system disorders: Jarisch-Herxheimer reaction (in patients with Lyme disease). Investigations: Increased BUN, liver enzymes (ALT, AST, alkaline phosphatase, gamma-glutamyl transferase, LDH). Nervous system disorders: Headache, dizziness, convulsion. Renal and urinary disorders: Decreased renal function, interstitial nephritis. Reproductive system and breast disorders: Vaginitis. Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria.
Potentially Fatal: Hypersensitivity reactions (e.g. angioedema, bronchospasm, anaphylaxis), Clostridium difficile-associated diarrhoea, pseudomembranous colitis; arrhythmia (rapid bolus inj via central venous catheter).
Drug Interactions
May potentiate the nephrotoxic effect of aminoglycosides, furosemide, and other nephrotoxic drugs. Delayed excretion and increased plasma concentration with probenecid. May decrease the efficacy of oral contraceptives.
CIMS Class
ATC Classification
J01DD01 - cefotaxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefotaxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in